Andrea Landorph

International Medical Director
Novo Nordisk A/S
Bagsværd, Hovedstaden, Denmark

Presentation(s):

• PB0523 - Interim results from a non-interventional, post authorisation safety study of nonacog beta pegol as routine prophylaxis in patients with haemophilia B

  Monday, June 24, 2024
  13:45 – 14:45 ICT